These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

999 related articles for article (PubMed ID: 19778774)

  • 41. Re-examining minimal luminal diameter relocation and quantitative coronary angiography--intravascular ultrasound correlations in stented saphenous vein grafts: methodological insights from the randomised RRISC trial.
    Semeraro O; Agostoni P; Verheye S; Van Langenhove G; Van den Heuvel P; Convens C; Van den Branden F; Bruining N; Vermeersch P;
    EuroIntervention; 2009 Mar; 4(5):633-40. PubMed ID: 19378685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. From debulking to delivery: sequential use of rotational atherectomy and Guidezilla™ for complex saphenous vein grafts intervention.
    Pellicano M; Floré V; Barbato E; De Bruyne B
    BMC Cardiovasc Disord; 2018 Jun; 18(1):122. PubMed ID: 29921223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of drug-eluting stents versus bare-metal stents in saphenous vein grafts lesions: a meta-analysis.
    Sanchez-Recalde A; Jiménez Valero S; Moreno R; Barreales L; Lozano I; Galeote G; Martín Reyes R; Calvo L; Lopez-Sendon JL
    EuroIntervention; 2010 May; 6(1):149-60. PubMed ID: 20542811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current percutaneous treatment strategies for saphenous vein graft disease.
    Marmagkiolis K; Grines C; Bilodeau L
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):406-13. PubMed ID: 22777812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-ST-segment elevation myocardial infarction related to vulnerable neoatheroma in bare-metal stents 2 years after percutaneous coronary intervention of a coronary saphenous vein graft.
    Roleder T; Wańha W; Smolka G; Ochała A; Wojakowski W
    JACC Cardiovasc Interv; 2014 Aug; 7(8):e95-6. PubMed ID: 25086848
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug Coated Balloon Is Less Effective for Treatment of DES In-Stent Restenosis Both in Native Coronary Arteries and Saphenous Vein Grafts: Results From a Bicenter Registry.
    Resch M; Ostheim P; Endemann DH; Debl K; Buchner S; Birner C; Maier LS; Kerber S; Luchner A; Griese DP
    J Interv Cardiol; 2016 Oct; 29(5):461-468. PubMed ID: 27477024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry.
    Brilakis ES; Wang TY; Rao SV; Banerjee S; Goldman S; Shunk K; Kar B; Holmes DR; Dai D; Chin CT; Harding TM; Roe MT
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1068-73. PubMed ID: 20965466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS).
    Morice MC; Feldman TE; Mack MJ; Ståhle E; Holmes DR; Colombo A; Morel MA; van den Brand M; Serruys PW; Mohr F; Carrié D; Fournial G; James S; Leadley K; Dawkins KD; Kappetein AP
    EuroIntervention; 2011 Oct; 7(6):670-9. PubMed ID: 21959312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study.
    Ellis SG; Kandzari D; Kereiakes DJ; Pichard A; Huber K; Resnic F; Yakubov S; Callahan K; Borgman M; Cohen SA
    J Invasive Cardiol; 2007 Oct; 19(10):404-9. PubMed ID: 17906340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term follow-up of lesion-specific outcomes comparing drug-eluting stents and bare metal stents in diseased saphenous vein grafts.
    Runyan D; Gorges R; Feldman D; McCullough PA; David S; Saba S
    Rev Cardiovasc Med; 2013; 14(1):1-6. PubMed ID: 23651982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts.
    Taniwaki M; Räber L; Magro M; Kalesan B; Onuma Y; Stefanini GG; van Domburg RT; Moschovitis A; Meier B; Jüni P; Serruys PW; Windecker S
    EuroIntervention; 2014; 9(12):1432-40. PubMed ID: 24064377
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts.
    Lee MS; Shah AP; Aragon J; Jamali A; Dohad S; Kar S; Makkar RR
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):507-11. PubMed ID: 16270361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Percutaneous intervention of a thrombotic-occluded saphenous vein graft successfully treated using the undersized stent approach to prevent distal embolization.
    Maluenda G; Alfonso F; Pichard AD
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):65-9. PubMed ID: 21328690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions.
    Jeger RV; Schneiter S; Kaiser C; Bonetti PO; Brunner-La Rocca H; Handke M; Osswald S; Buser PT; Pfisterer ME;
    Cardiology; 2009; 112(1):49-55. PubMed ID: 18580059
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease.
    Ramana RK; Ronan A; Cohoon K; Homan D; Sutherland J; Steen L; Liu J; Loeb H; Lewis BE
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):886-93. PubMed ID: 18412238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions: insights from the Veterans Affairs CART program.
    Aggarwal V; Stanislawski MA; Maddox TM; Nallamothu BK; Grunwald G; Adams JC; Ho PM; Rao SV; Casserly IP; Rumsfeld JS; Brilakis ES; Tsai TT
    J Am Coll Cardiol; 2014 Oct; 64(17):1825-36. PubMed ID: 25443706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.